

Drug Utilization Review Board Meeting

June 21, 2012

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
New Drug Reviews			
Antihemophilic Agent			
	Corifact	P	P/PA
Chelating Agent			
	Ferriprox	NP/PA	NP/PA
Antineoplastic			
	Jakafi	P	P
Agent for Gaucher Disease			
	Vpriv	P/PA	P/PA
Class Reviews			
Protease Inhibitors for Hepatitis C			
	Incivek	NP/PA	P/PA
	Victrelis	NP/PA	P/PA
Agents for Hereditary Angioedema			
	Berinert	P	P
	Cinryze	P	P
	Firazyr	P	P
	Kalbitor	P	NP
Atypical Antipsychotics			
	Abilify	NP/PA	P/PA after one generic trial
	clozapine (Clozaril, Fazaclo)	NP/PA<18yo	NP/PA<18yo
	olanzapine generic	NP/PA	P/PA<13yo
	Zyprexa/Zydis/Relprevv	NP/PA	NP/PA
	Symbyax	NP/PA	NP/PA

	quetiapine generic	NP/PA	P/PA<10yo
	Seroquel	P/PA<10yo	NP/PA
	Seroquel XR	NP/PA	NP/PA
	risperidone generic	P/PA<10yo	P/PA<10yo
	Risperdal/M-Tab/Consta	NP/PA	NP/PA
	ziprasidone generic	NP/PA	P/PA<18yo
	Geodon	P/PA<18yo	NP/PA
	Saphris	NP/PA	NP/PA
	Fanapt	NP/PA	NP/PA
	Latuda	NP/PA	P/PA after one generic trial
	Invega/Sustenna	NP/PA	NP/PA
	Equetro	P	P
Growth Hormones			
	Genotropin	P/PA	P/PA
	Humatrope	NP/PA	NP/PA
	Norditropin	P/PA	P/PA
	Nutropin/AQ	P/PA	P/PA
	Omnitrope	NP/PA	NP/PA
	Saizen	NP/PA	NP/PA
	Tev-Tropin	NP/PA	NP/PA
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)			
	Cymbalta	NP/PA	NP/PA
	Pristiq	NP/PA	NP/PA
	Savella	NP/PA	NP/PA
	Venlafaxine ER Tablets	NP/PA	NP/PA

Non-Supplemental Rebate Class Reviews

Non-Supplemental Rebate Class Reviews	
Analgesics – Miscellaneous	No Change – Leave as is
Anaphylaxis Therapy	No Change – Leave as is
Angiotensin Converting Enzyme Inhibitors and Calcium Channel Blockers Combinations	No Change – Leave as is
Antifungals	No Change – Leave as is
Beta Adrenergics – Long-Acting Nebulizers	No Change – Leave as is
Beta Adrenergics – Short-Acting Nebulizers	No Change – Leave as is
Diabetic – Meglitinides	No Change – Leave as is
Diabetic – Thiazolidinediones	No Change – Leave as is
Fluoroquinolones	No Change – Leave as is
Gastrointestinal – Proton Pump Inhibitors	No Change – Leave as is
Herpes Agents – Oral	No Change – Leave as is
Immunosuppressants – Renal Transplant Rejection Agents	No Change – Leave as is
Narcotics – Miscellaneous	No Change – Leave as is
Ophthalmics – Miscellaneous	No Change – Leave as is
Osteoporosis Agents	No Change – Leave as is
Parkinson’s Disease – Selective Dopamine Agonists	No Change – Leave as is
Topical – Antivirals	No Change – Leave as is
Topical – Genital Warts	No Change – Leave as is
Urinary Antiinfectives	No Change – Leave as is

PDL = Preferred Drug List; P = Preferred; NP = Non-Preferred; PA = Prior Authorization